5 research outputs found

    Influence of different polishing materials in the material removal of steel samples

    Get PDF
    The quality of injection moulded polymer optic parts depends on the surface finish of the respective mould. In order to improve and control the surface finish of the mould it is important to be able to keep the material removal constant during the polishing process of these moulds. This will provide a tactical material removal therefore allowing a controlled correction of the mould’s surface geometry. The aim of this work is to study the influence of different polishing materials in the material removal rate and its reproducibility during the polishing process of hardened steel. Different polyurethane polishing materials with different fillers were tested. It was observed that the filler material of the polyurethane is crucial in order to obtain constant and reproducible results. Experiments were carried out with an industrial robot and the material removal’s depth value was compared

    Material removal simulation for steel mould polishing

    Get PDF
    The surface finish of an injection mould influences the quality of the moulded polymer optic parts. In order to improve and control the surface finish of the mould it is important to be able to predict the material removal during the polishing process of this mould. The aim of this work is to predict the material removal during the polishing process, comparing the results obtained from polishing attempts on steel samples and the results obtained from a simulation model. A simulation model is developed with the abrasive wear Holm-Archard equation in ANSYS. This simulation model will help to eliminate the iterative trial and error polishing, therefore facilitating the steel mould production

    The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

    Get PDF
    Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

    The Changing Landscape for Stroke\ua0Prevention in AF

    No full text

    The Changing Landscape for Stroke Prevention in AF

    No full text
    corecore